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ABSTRACT
Background: There is convincing evidence that daily whole almond
consumption lowers blood LDL cholesterol concentrations, but
effects on other cardiometabolic risk factors such as endothelial
function and liver fat are still to be determined.
Objectives: We aimed to investigate whether isoenergetic substi-
tution of whole almonds for control snacks with the macronutrient
profile of average snack intakes, had any impact on markers of
cardiometabolic health in adults aged 30–70 y at above-average risk
of cardiovascular disease (CVD).
Methods: The study was a 6-wk randomized controlled, parallel-
arm trial. Following a 2-wk run-in period consuming control snacks
(mini-muffins), participants consumed either whole roasted almonds
(n= 51) or control snacks (n= 56), providing 20% of daily estimated
energy requirements. Endothelial function (flow-mediated dilation),
liver fat (MRI/magnetic resonance spectroscopy), and secondary
outcomes as markers of cardiometabolic disease risk were assessed
at baseline and end point.
Results: Almonds, compared with control, increased endothelium-
dependent vasodilation (mean difference 4.1%-units of measure-
ment; 95% CI: 2.2, 5.9), but there were no differences in liver fat
between groups. Plasma LDL cholesterol concentrations decreased
in the almond group relative to control (mean difference −0.25
mmol/L; 95%CI:−0.45,−0.04), but there were no group differences
in triglycerides, HDL cholesterol, glucose, insulin, insulin resistance,
leptin, adiponectin, resistin, liver function enzymes, fetuin-A, body
composition, pancreatic fat, intramyocellular lipids, fecal SCFAs,
blood pressure, or 24-h heart rate variability. However, the long-
phase heart rate variability parameter, very-low-frequency power,
was increased during nighttime following the almond treatment
compared with control (mean difference 337 ms2; 95% CI: 12, 661),
indicating greater parasympathetic regulation.
Conclusions: Whole almonds consumed as snacks markedly im-
prove endothelial function, in addition to lowering LDL choles-
terol, in adults with above-average risk of CVD. This trial was
registered at clinicaltrials.gov as NCT02907684. Am J Clin Nutr
2020;111:1178–1189.
Keywords: almonds, endothelial function, liver fat, dietary interven-
tion, cardiovascular disease, cardiometabolic disease
Introduction
Cardiovascular disease (CVD) continues to be the leading
cause of global mortality. The development of CVD is pre-
ceded by cumulative interrelated hemodynamic and metabolic
disturbances that develop over the life course and also feature
in the pathophysiological progression to type 2 diabetes (T2D)
(1). Dietary guidelines have been formulated partly to mitigate
the progression of cardiometabolic risk phenotypes, such as
raised blood pressure, dyslipidemia, and central adiposity, by
encouraging a healthy eating pattern, limiting intake of added
sugars, SFAs, and sodium, and choosing nutrient-dense foods
in all food groups (2, 3). Most people in the United States
and United Kingdom consume ≥2 snacks/d, contributing ∼20–
25% of energy intake on average (4, 5). Data derived from
respondents to the UK National Diet and Nutrition Survey
2008–2012 revealed that the average snack nutrient profile had
14% of energy as saturated fats and 23% of energy as sugars
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(predominantly added sugars) (6), exceeding dietary reference
values for upper limits of their intake. Therefore, snacks present
an easily modifiable target for improving overall diet quality.
Whole nuts, for example, almonds, which are mainly eaten
as snacks, are encouraged as part of recommended healthy
eating patterns because they are rich in protein, dietary fiber,
unsaturated fatty acids, and micronutrients (vitamin E, riboflavin,
niacin, and magnesium) (7, 8), and could displace other snack
foods that are rich in SFAs, refined starch, and added sugar,
and low in fiber. Inclusion of almonds in the diet is associated
with reduced risk of CVD and T2D, and higher intakes
can lower plasma LDL cholesterol and fasting blood glucose
concentrations without leading to any increase in body weight
(9, 10). Almond skin is a source of nonnutrient bioactives, for
example, (poly)phenolic compounds, that can play a role in the
mechanism of CVD prevention (11, 12). Almonds also contain
significant amounts of l-arginine, the biological precursor of the
potent vasodilator, nitric oxide, and they are a natural source
of phytosterols, which can contribute to the LDL cholesterol–
lowering properties of almonds to a limited extent (13). However,
the impact of regular whole almond consumption on endothelial
function, a key factor in the initiation, progression, and disease
manifestation of atherosclerosis, is not yet known. Endothelial
function is adversely affected by chronic low-grade inflammation
and increased oxidative stress, which are pathological features
associated with obesity, fatty liver, and insulin resistance. Dis-
placement of SFAs and refined carbohydrates from typical snack
products consumed in industrialized countries with unsaturated
fats, protein, and fiber from whole almonds, could potentially
reduce liver fat, which can subsequently impact cardiometabolic
risk.
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This dietary intervention trial (Almonds Trial Targeting
Dietary Intervention with Snacks, or ATTIS) was designed to
compare the effects of replacing habitual daily snacks with
either whole almonds or control snacks with a nutritional profile
matching the average UK macronutrient intakes from snacks
(excluding fruit) on endothelial function and liver fat, the
primary outcomes. Secondary outcomes included blood glucose,
insulin, lipid profile, adipokines, markers of fatty liver, body
composition, blood pressure, heart rate variability, pancreatic
and skeletal muscle fat, fecal SCFAs, plasma fatty acid profiles,
and metabolomic profiles. It was hypothesized that substituting
whole almonds for typically consumed snacks would increase
endothelium-dependent vasodilation and decrease liver fat.
Methods
Study population
Study participants were adult men and women (aged 30–
70 y), with above-average risk of developing CVD, and self-
reported regular snack consumers (≥2 snacks/d) recruited from
London, United Kingdom, and the surrounding area between
March 2017 and January 2019. Further details are given in
Supplemental Methods. A CVD risk score system adapted from
the Framingham risk score systemwas used to identify volunteers
(scoring ≥2) who were above-average risk (14). Inclusion and
exclusion criteria are detailed in Supplemental Table 1. All
participants gave written informed consent before enrollment.
Study design
The ATTIS study, conducted between March 2017 and May
2019, was approved by the UK National Research Ethics
Service (REC 16/LO/1910) and registered with clinicaltrials.gov
(NCT02907684). The trial was run in accordance with the
Declaration of Helsinki and the principles of Good Clinical
Practice.
The study was a randomized, parallel-arm design with 2
intervention groups, almonds and control, in a free-living
cohort. Treatment was randomly allocated by the lead researcher
using minimization software (MinimPy 0.3; Mahmoud Saghaei;
http://minimpy.sourceforge.net), with age, sex, ethnicity, car-
diometabolic score, and willingness to undergo MRI/magnetic
resonance spectroscopy (MRS) scanning as minimization vari-
ables. A 2-wk run-in period consuming control snacks preceded
random allocation to ensure that the study protocol was tolerable
to individual participants prior to starting the intervention phase,
and to collect baseline diet and physical activity data. Body
composition, clinic blood pressure (BP), and 24-h ambulatory
blood pressure (ABP) were measured; 4-d food and activity
diaries were collected. Participants abstained from alcohol and
strenuous activity for 24 h before baseline and end-point clinic
visits, and consumed low-fat meals and no alcohol in the
evening before. Figure 1 shows the timeline of study visits and
measurements. In brief, during the 6-wk intervention period,
participants attended 4 visits. Baseline and end-point visits
(separated by 6 wk) involved measurements of flow-mediated
dilation (FMD) to assess endothelial function; MRI/MRS scan to
assess liver, pancreas, and abdominal fat and myocellular lipids;
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FIGURE 1 Almonds Trial Targeting Dietary Intervention with Snacks (ATTIS) study design flowchart. MRS, magnetic resonance spectroscopy.
insulin, lipids, and adipokines; and stool samples for fecal
SCFAs. Intermediate visits (weeks 2 and 4 of the randomized
intervention period) includedmeasurements of body composition
and clinic BP, and completion of a 24-h dietary recall to monitor
compliance to intervention.
Dietary intervention
The dietary intervention included a 2-wk run-in period, during
which participants consumed control snacks providing 20%
of estimated energy requirement (EER), followed by random
allocation to either control or almond snacks at 20% of EER.
Henry equations and physical activity level estimated from 4-
d activity diaries were used to calculate EER (15). Sweet and
savory mini-muffins were baked at the study center as the control
snacks; these were formulated to provide a macronutrient profile
that was representative of the average macronutrient intakes from
snacks (excluding fruit) in the UK National Diet and Nutrition
Survey population (6), as detailed in Supplemental Methods
and Supplemental Table 2. Almond snacks were dry-roasted
whole nonsalted almonds of the Nonpareil variety, supplied by
the Almond Board of California (US grade extra no. 1). The
whole almonds were weighed and packed in a daily portion for
each subject. For example, 63 g (2.2 oz, or 14 cup) of almonds
were provided daily for an individual estimated to require 2000
kcal (8.37MJ) (Supplemental Methods and Supplemental Table
3). During run-in and intervention periods, participants were
provided with snack information sheets and dietary advice from
the research dietitian and instructed to only consume study snacks
between meals and to maintain their habitual mealtime eating
habits and fruit consumption. All subjects were asked to avoid the
consumption of additional nuts or nut products for the duration
of the study.
Outcomes
Required sample sizes were calculated for specified primary
outcomes based on a 1.25% unit difference in a similar study
of walnuts (SD: 1.9) in FMD (16), a measure of endothelium-
dependent vasodilation (EDV), and a 2.2% unit difference in liver
fat (intrahepatic lipid, IHL) between groups as being clinically
important. A sample size of 50 subjects per treatment group had
90% power to detect a 1.25% unit effect of treatment on FMD
with a 2-tailed α of 0.05. For liver fat, 20 subjects per group was
sufficient to detect a 2.2% unit change (SD: 2.1) (17) with 90%
power and a 2-tailed α of 0.05.
Endothelial function
Following 15 min of supine rest, endothelial function was
assessed as EDV of the brachial artery using the FMD technique
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(18). FMD was also measured post glycerol trinitrate (GTN)
administration to determine endothelium-independent vasodila-
tion. Scans were evaluated using Brachial Analyzer software
(Medical Imaging Applications LLC) by a single researcher
who was blinded to the identity of the participant and treatment
allocation.
Liver fat
Fifty subjects, 25 in each treatment group, agreed at screening
to undergo MRI scanning. For quantification of IHL by MRI,
participants were scanned from neck to foot in the supine position
following an overnight fast on a 1.5-T Siemens Magnetom
Aera scanner at baseline and end-point visits. The magnetic
resonance protocol from which fat and water images were
produced as part of the 6-point Dixon sequence was as follows
(19): 8 contiguous stations covering neck-foot, acquisition time
(TA) 16 s; 56 slices, field of view (FoV) 500 × 72.3%,
acquired voxel size 2.2 × 2.2 × 3.5 mm, 7/8 phase and slice
partial Fourier, 28.6% slice oversampling, acceleration factor 2
(CAIPIRINHA, controlled aliasing in parallel imaging results in
higher acceleration; a data acquisition technique that facilitates
high-resolution images for breath-hold examinations), flip angle
4◦, and slice thickness 3.5 mm. To reduce motion artifacts,
participants were instructed to hold their breath for 15 s while
abdominal images were acquired. Liver fat was quantified using
HOROS V 1.1.7 software (available at: www.horosproject.o
rg) by a single analyst who was blinded to the participant
identification code and treatment allocation of clinical data.
Four regions of interest (ROIs) were placed on each slice of
abdominal cavity images where the liver was visually the major
sized organ in the images, avoiding blood vessels, bile ducts,
and obvious artifacts (20). The ROIs were drawn in 2-point
Dixon to have details of liver images visualized more clearly
including vessels and ducts, and then copied and pasted into
6-point Dixon sequence. The 2-point Dixon protocol was as
follows: TA 13 s; 56 slices, FoV 500 × 72.3%, acquired voxel
size 1.1 × 1.1 × 3.5 mm, 7/8 phase and slice partial Fourier,
28.6% slice oversampling, acceleration factor 2 (CAIPIRINHA),
flip angle 12◦, and slice thickness 3.5 mm. Hepatic fat fraction
was calculated in each ROI by using the mean of pixel signal
intensity, and IHL was calculated as the mean of all ROIs in each
slice.
IHL, alongside lipid saturation/unsaturation, was also quan-
tified by proton magnetic resonance spectroscopy (1H-MRS)
according to previously reported methods (21). MRS spectra
were analyzed on the Java-based Magnetic Resonance User
Interface (jMRUI) software with the inclusion of prior knowledge
to assist in identification of the peaks of interest. Prior knowledge
of a 5-resonance model was applied to fit the lipid peaks:
diallylic protons [-(CH2)n, ∼2.9 ppm], methylenic protons (-
CH2, ∼2.3 ppm) in the α position relative to the carboxyl
group, allylic protons [-(CH2)n, ∼2.0 ppm], IHL/methylene
protons [-(CH2)n, ∼1.3 ppm], and methyl protons (-CH3,
∼0.9 ppm). The formulas were used to determine the un-
saturation index, polyunsaturation index, and saturation index
of the liver fat, as previously explained by Johnson et al.
(21).
Intrapancreatic lipid, intramyocellular lipids, and body
composition
Intrapancreatic lipid (IPL) quantification was measured by 2-
point Dixon sequence MRI scanning. One circular 1-cm2 ROI
was drawn on the head, body, and tail regions of the pancreas.
IPL was quantified from each ROI using the formula: %IPL
= [F/(F + W)] × 100, where F and W are the pixel signal
intensities of the fat and water images, respectively. Mean IPL
was calculated as the mean of the head, body, and tail IPL.
A consultant radiologist checked and confirmed the position
of ROIs. Intramyocellular lipid (IMCL) and extramyocellular
lipid (EMCL) of the soleus muscle of the calf were quantified
by 1H-MRS according to previously reported methods (22).
To fit the lipid peaks for IMCL and EMCL quantification, the
model used was as follows (22): water resonance 4.7 ppm,
choline 3.2 ppm, creatine 3.0 ppm, EMCL-CH2 1.5 ppm, IMCL-
CH2 1.3 ppm, EMCL-CH3 1.1 ppm, and IMCL-CH3 0.9 ppm.
IMCL and EMCL were quantified as the ratio of the methylene
IMCL or EMCL peaks (IMCL-CH2 or EMCL-CH2) to internal
water.
Images for the estimation of truncal visceral adipose tissue
(VAT) and subcutaneous adipose tissue (SAT) volumes were
obtained from the top of the acquisition (neck) to the last slice
of the abdominopelvic cavity by the same 6-point Dixon MRI
scanning protocol described for liver fat, and quantification was
performed using artificial intelligence–based image processing
software developed at the University of Westminster, London,
United Kingdom. Body weight and percentage body fat by
bioelectrical impedance analysis were also measured (Tanita BC-
418MA; Tanita Ltd).
Blood pressure and heart rate variability
Ambulatory blood pressure (ABP) was measured using TM-
2430 ABP monitors (A&D Inc) worn for 24 h. Readings were
obtained every 30 min during daytime and every 60 min at night
(22:00 to 07:00). Participants kept a record of their physical
activity and sleep time in a 24-h activity diary, with self-
reported sleep cutoffs being used in the analysis of daytime and
nighttime BP. A&D Professional Analysis software was used to
analyze mean 24-h, daytime, and nighttime SBP, DBP, and pulse.
OMRON M2 Basic Intellisense monitors (OMRON Healthcare
UK Ltd) were used to measure clinical blood pressure according
to British Hypertension Society guidelines (23).
A small, lightweight, chest-worn, wireless 2-lead ambulatory
heart rate/ECG monitor (eMotion Faros 180, Mega Electronics
Ltd) was fitted to measure 24-h ambulatory HRV (24 h, daytime
and nighttime). Time-domainHRVparameters included themean
of the SDs of the normal-to-normal (NN) intervals (SDNN)
and root mean square of successive differences of NN intervals
(RMSSD). Frequency-domain HRV parameters included high-
frequency (HF) power and very-low-frequency (VLF) power.
Real-time HRV was recorded during a 5-min rest, a 5-min
physical stressor (inflation of blood pressure monitor cuff to
200 mmHg), and a mental stressor [the Stroop color-word test
(24)]. Cardiscope Analytics software (HASIBAMedical GmbH)
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Blood biomarkers and fecal SCFAs
Blood and fecal sample collection procedures and analysis
are explained in Supplemental Methods. Fasting insulin, glucose,
nonesterified fatty acids, plasma lipids [total cholesterol (TC),
HDL cholesterol, LDL cholesterol, triglyceride, and calculated
TC:HDL cholesterol ratio], fatty liver indicators [fetuin-A, γ -
glutamyltransferase (GGT), and alanine transaminase (ALT)],
clinically relevant biomarkers of metabolic dysregulation/insulin
resistance (adiponectin, resistin, and leptin), plasma fatty acids,
and metabolomics were analyzed using venous blood samples
taken at baseline and end point. Metabolomic profiling was
performed using a high-throughput serum NMR metabolomics
platform (Nightingale Health), as described by Soininen et al.
(26). All blood samples were processed by laboratory technicians
blinded to participant identification and treatment allocation.
Fecal samples were collected at baseline and end point in a subset
of participants (n = 18 almond group, n = 17 control group) and
processed within 2 h before analysis by gas chromatography, as
described in Supplemental Methods.
Compliance and dietary assessment
As outlined in Figure 1, compliance with the dietary advice
was verified by telephone 24-h recalls and 4-d estimated portion
size food records, which were analyzed using Nutritics software
(v5.026; Nutritics Ltd) and inspection of stool samples for
almond particles. Compliance scores included: 1) complete
consumption of study snacks; 2) avoidance of consumption of
other snacks; and 3) avoidance of consumption of nuts other
than almonds, as assessed by 4-d food diaries and 24-h dietary
recall. The scores were as follows: score 0—did not comply;
score 1—partial compliance; score 2—moderate compliance;
score 3—full compliance. For participants who did not complete
4-d food diaries, the compliance was checked based solely on
24-h dietary recalls. Explanations for missing data are provided
in Supplemental Figure 1.
Statistical analysis
Statistical analysis was performed using IBM SPSS 25.
Normality of data was assessed visually using histogram and Q-
Q plot of residuals. Baseline data are shown as mean value and
SD, or, if not normally distributed, as median (IQR). Treatment
effects are presented as adjusted marginal mean differences of
change between end-point and baseline values of the 2 groups and
95% CI. A chi-square test was conducted to investigate whether
there were differences in sex and ethnicity between control
and almond groups at baseline. To examine whether there were
differences in other baseline characteristics and also in baseline
data between the two treatment groups, independent t tests were
used for normally distributed data, and a Mann–Whitney U test
was used for nonnormally distributed data. To investigate the
significance of treatment effects between the 2 groups, ANCOVA
was used, with change from baseline as the dependent variable,
adjusting for baseline value and baseline BMI; analysis results
are presented as change values from baseline generated from
estimated marginal means with CI. In addition to normality
checks of residuals distribution of the changes, homogeneity of
variance was examined by plotting standardized residual values
compared with predicted values, and also by using Levene tests.
A 2-sided P value <0.05 was considered to show statistical
significance.
Results
TheCONSORTflow diagram, showing the flow of participants
through the study, is shown in Supplemental Figure 1. Of 294
potential participants interested in taking part in the study, 109
were eligible and 107 were randomly allocated to control or
almond treatments. One hundred and five participants completed
the trial: 51 in the control group and 54 in the almond group.
Reasons for noncompletion included gastrointestinal intolerance
of almonds (n = 2). The baseline characteristics of study
participants randomly allocated to treatment were not different
between the control and almond groups (shown in Table 1).
Approximately 30% of participants were male and 70% female,
and ∼37% identified as belonging to an ethnic group other than
white.
Compliance with dietary intervention
Compliance with the intervention was high as evidenced by
mean (±SD) compliance scores of 2.8± 0.3 in the almond group
and 2.7 ± 0.4 in the control group, out of a possible maximum of
3. Only 80 participants completed both sets of food diaries as per
instructions with satisfactory data quality, but compliance scores
based on 24-h dietary recalls did not differ significantly between
those who completed both food diaries adequately and those who
did not [mean compliance for food diary completers in almond
group 2.9 ± 0.3 (n = 40), in control group 2.7 ± 0.4 (n = 40);
for food diary noncompleters in almond group 2.9± 0.3 (n= 14)
and control group 2.5 ± 0.6 (n = 11)].
Table 2 shows the nutrient intake of the study population
as measured from 4-d diet diaries at baseline (week 0) and
end of intervention from the 40 participants of each group who
completed diaries at both time points. At baseline, SFAs provided
12.3% and 12.5% of energy intake, and free sugars provided
5.9% and 5.5% of energy intake for the control and almond
groups, respectively. There was no difference in the change from
baseline in energy intake between control and almond groups
during the intervention. Relative to the control group, the almond
group reduced intakes of total carbohydrates, starch, and free
sugars as a percentage of energy intake by 9.3%, 7.0%, and
3.0%, respectively, and increased dietary fiber intake by 7.4%.
Total fat intake as a percentage of energy intake and the ratio of
unsaturated to saturated fatty acids were significantly increased
in the almond group, by 10.8% and 1.3%, respectively, compared
with the control group. The almond group also increased intakes
of potassium, magnesium, vitamin E, and riboflavin, and lowered
intake of sodium relative to the control group.
To determine whether pre–post intervention changes were
significant in the almond group but not the control group, repeated
measures ANCOVA (with time as a repeated measure and BMI
as covariate) showed that the decreases in carbohydrate, starch,
free sugars, and sodium intakes in the almond group were
significant (time × intervention group interactions are presented
in Supplemental Table 4), whereas there were no significant
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TABLE 1 Participant characteristics at screening for those randomized to treatment1
Control, n = 51 Almond, n = 56
Age, y 56.0 ± 10.7 56.3 ± 10.3
Sex, M/F, n 15/36 17/39
Ethnicity (black/South Asian, Southeast Asian, and Middle
Eastern/Far East/white/other), n
2/6/2/34/7 9/7/3/34/3
Cardiometabolic score 4.2 ± 2.1 4.5 ± 2.0
BMI, kg/m2 26.7 ± 4.5 27.3 ± 4.4
Waist circumference, cm 93.3 ± 12.5 93.6 ± 12.5
Body fat, % 32.7 ± 8.5 34.4 ± 8.4
cSBP, mmHg 124.4 ± 15.1 126.2 ± 17.6
cDBP, mmHg 80.6 ± 7.7 83.8 ± 10.8
Glucose, mmol/L 5.1 ± 0.6 5.1 ± 0.5
TC, mmol/L 5.6 ± 1.2 5.6 ± 1.0
TAG, mmol/L 1.2 ± 0.5 1.2 ± 0.6
LDL, mmol/L 3.5 ± 1.0 3.4 ± 0.9
HDL, mmol/L 1.6 ± 0.5 1.6 ± 0.5
TC:HDL 3.6 ± 0.9 3.7 ± 1.1
1Values are means ± SD or categorical totals. Ethnicity was determined by self-reporting. Chi-square test was
used to examine whether there were differences in sex and ethnicity. Independent t test was used to examine whether
there were differences in other characteristics. There were no differences between groups for any of the parameters
included in this table. cDBP, clinical diastolic blood pressure; cSBP, clinical systolic blood pressure; TAG,
triglyceride; TC, total cholesterol.
the increases in intakes of dietary fiber, fat, MUFAs, PUFAs,
the ratio of unsaturated to saturated fatty acids, and vitamin
E in the almond group were significant, but there were no
significant changes in the control group. Potassium, magnesium,
and riboflavin significantly increased in the almond group but
also significantly decreased in the control group, although the
magnitude of the changes was smaller in the control group for
magnesium and riboflavin. There were no significant changes in
total energy, SFA, protein, and niacin intake within either group.
Vascular health
Vascular-related measures are shown in Table 3. There was
a significant treatment difference in the change from baseline
values for FMD. Almond consumption significantly increased
FMD by 4.1% units relative to the change following control
snacks (95% CI: 2.2, 5.9% units; P < 0.00005). There were
no differential changes in baseline brachial artery diameter
or in endothelium-independent vasodilation (following GTN)
between groups. VLF power, a frequency domain parameter of
TABLE 2 Nutrient intakes estimated from 4-d food diaries at baseline (prior to run-in) and the final week of the dietary intervention1
Control,2 nmax = 40 Almond,2 nmax = 40
Mean comparison
between groups P valueBaseline Change Baseline Change
Energy intake,3 kcal/d 2088.9 ± 538.5 − 5.8 (−124.7, 113.2) 1769.4 ± 475.0 − 85.3 (−204.3, 33.7) − 79.5 (−251.8, 92.8) 0.361
Protein, %E 15.4 ± 3.8 0.5 (−0.5, 1.5) 15.9 ± 3.6 1.0 (0.0, 2.0) 0.5 (−0.9, 1.9) 0.466
Total carbohydrate, %E 43.3 ± 7.1 1.7 (−0.1, 3.5) 41.8 ± 6.6 − 7.6 (−9.4, −5.8) − 9.3 (−11.9, −6.8) <0.001
Starch, %E 23.9 ± 5.1 2.5 (0.9, 4.1) 23.5 ± 5.3 − 4.5 (−6.1, −2.9) − 7.0 (−9.3, −4.8) <0.001
Free sugars, %E 5.9 ± 3.8 0.4 (−0.5, 1.2) 5.5 ± 2.8 − 2.6 (−3.5, −1.8) − 3.0 (−4.2, −1.8) <0.001
Dietary fiber,3 g/d 23.8 ± 6.2 − 1.9 (−4.5, 0.6) 20.7 ± 7.7 5.5 (3.0, 8.1) 7.4 (3.8, 11.1) <0.001
Fat, %E 36.5 ± 6.5 − 2.6 (−4.3, −0.8) 37.1 ± 6.2 8.3 (6.5, 10.0) 10.8 (8.4, 13.3) <0.001
SFA, %E 12.3 ± 3.6 − 0.6 (−1.3, 0.1) 12.5 ± 3.7 − 1.4 (−2.1, −0.6) − 0.7 (−1.8, 0.3) 0.153
MUFA, %E 11.5 ± 3.4 − 1.1 (−2.4, 0.0) 12.4 ± 3.7 8.6 (7.4, 9.8) 9.8 (8.1, 11.5) <0.001
PUFA, %E 5.9 ± 2.5 − 0.8 (−1.4, −0.1) 5.9 ± 1.7 2.0 (1.4, 2.6) 2.8 (1.9, 3.7) <0.001
Unsaturated:saturated
fatty acid ratio
− 0.1 ± 0.6 − 0.1 (−0.3, 0.1) 1.1 ± 1.1 1.1 (0.9, 1.3) 1.3 (1.0, 1.5) <0.001
Sodium, mg 2151.2 ± 766.3 179.7 (−15.8, 375.3) 1926.1 ± 866.1 − 490.8 (−686.4, −295.3) − 670.6 (−948.6, −392.6) <0.001
Potassium,3 mg 3028.9 ± 936.2 − 352.5 (−590.4, −114.5) 2534.7 ± 854.5 221.3 (−16.7, 459.3) 573.8 (231.0, 916.6) 0.001
Calcium,3 mg 868.4 ± 455.8 24.2 (−57.6, 106.0) 703.8 ± 242.5 57.3 (−24.5, 139.0) 33.1 (−84.0, 150.2) 0.575
Magnesium,3 mg 368.7 ± 180.9 − 36.0 (−68.9, −3.0) 278.5 ± 92.1 112.6 (79.7, 145.5) 148.6 (100.9, 196.3) <0.001
Vitamin E, mg 10.7 ± 3.7 − 1.9 (−3.5, −0.4) 8.9 ± 4.0 13.5 (11.9, 15.0) 15.4 (13.2, 17.6) <0.001
Riboflavin, mg 1.8 ± 1.6 − 0.1 (−0.3, 0.0) 1.5 ± 0.8 0.4 (0.2, 0.6) 0.5 (0.3, 0.8) <0.001
Niacin, mg 16.1 ± 8.9 − 1.6 (−3.3, 0.1) 14.7 ± 9.4 − 0.4 (−2.1, 1.3) 1.2 (−1.3, 3.6) 0.339
1Baseline data are mean ± SD. Values of change and main comparisons of changes between groups are presented as mean (95% CI) generated from estimated marginal means
from ANCOVA, adjusted for baseline value and baseline BMI. ANCOVA assumptions were met. P < 0.05 indicates a significant difference. .
2Data were analyzed using 40 diaries collected from each group. Missing data are due to poor quality of diet diaries or failure to complete by participant.
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TABLE 3 Changes in indices of vascular function, blood pressure, and heart rate variability following randomization to almond and control snacks1
Control,2 nmax = 51 Almonds,2 nmax = 54
Main comparison
between groups4Baseline3 Change Baseline3 Change
Endothelium-dependent vasodilation
FMD,5 % 7.0 ± 4.8 − 0.8 (−2.1, 0.5) 3.6 ± 3.9 3.3 (2.0, 4.5) 4.1 (2.2, 5.9)6
Prehyperemia brachial artery diameter, mm 3.49 ± 0.58 0.00 (−0.09, 0.09) 3.56 ± 0.48 − 0.01 (−0.09, 0.08) − 0.01 (−0.14, 0.11)
GTN, % 14.8 ± 6.5 − 0.2 (−1.6, 1.3) 12.6 ± 4.9 0.7 (−0.6, 2.0) 0.9 (−1.1, 2.9)
Clinic blood pressure
cSBP, mmHg 127.8 ± 12.9 − 5.2 (−7.9, −2.6) 127.3 ± 19.3 − 6.3 (−8.9, −3.7) − 1.0 (−4.7, 2.6)
cDBP, mmHg 84.6 ± 7.9 − 3.2 (−5.1, −1.3) 85.5 ± 10.6 − 3.5 (−5.3, −1.6) 0.2 (−2.9, 2.4)
Ambulatory blood pressure
24-h SBP,5 mmHg 122.7 ± 9.7 0.4 (−2.0, 2.8) 128.0 ± 15.0 − 1.0 (−3.3, 1.3) − 1.4 (−4.8, 1.9)
24-h DBP,5 mmHg 74.1 ± 6.2 − 0.2 (−1.9, 1.5) 77.6 ± 9.3 − 0.6 (−2.3, 1.0) − 0.4 (−2.8, 2.0)
24-h pulse, beats/min 71.9 ± 8.4 − 0.4 (−2.2, 1.4) 72.6 ± 9.3 − 1.0 (−2.8, 0.7) − 0.7 (−3.2, 1.9)
Daytime SBP,5 mmHg 126.1 ± 9.8 − 0.1 (−2.7, 2.6) 132.6 ± 16.0 − 0.4 (−2.9, 2.2) − 0.3 (−4.1, 3.5)
Daytime DBP,5 mmHg 76.2 ± 6.5 0.1 (−1.8, 2.1) 80.9 ± 9.9 − 0.2 (−2.0, 1.7) − 0.3 (−3.1, 2.4)
Daytime pulse, beats/min 74.5 ± 8.5 0.1 (−1.9, 2.1) 75.3 ± 9.5 − 1.3 (−3.3, 0.6) − 1.1 (−4.2, 1.3)
Nighttime SBP, mmHg 109.3 ± 11.9 1.2 (−1.9, 4.9) 111.6 ± 15.3 − 1.0 (−4.3, 2.4) − 3.0 (−7.2, 1.3)
Nighttime DBP, mmHg 64.6 ± 7.6 − 0.1 (−2.3, 2.0) 65.6 ± 8.5 − 1.4 (−3.4, 0.6) − 1.3 (−4.2, 1.6)
Nighttime pulse, beats/min 61.5 ± 8.1 − 0.8 (−2.7, 1.0) 63.0 ± 9.7 − 0.2 (−1.9, 1.5) 0.7(−1.8, 3.2)
Heart rate variability (24 h and nighttime)
24-h SDNN, ms 148.8 ± 36.5 − 8.2 (−17.3, −0.9) 142.2 ± 35.0 − 5.2 (−14.9, 4.5) 3.0 (−10.3, 16.4)
24-h rMSSD, ms 28.5 ± 8.9 1.9 (−0.6, 4.3) 30.5 ± 9.8 0.6 (−2.1, 3.2) − 1.3 (−4.9, 2.3)
Nighttime SDANN, ms 64.1 ± 22.3 − 0.8 (−8.3, 6.8) 66.5 ± 33.0 1.0 (−6.4, 8.4) 1.8 (−8.8, 12.3)
Nighttime rMSSD, ms 31.3 (20.9) 1.9 (−1.3, 5.0) 33.9 (17.4) − 1.1 (−4.1, 1.9) − 3.0 (−7.3, 1.4)
Nighttime VLF, ms2 1664 (2720) − 293 (−523, −62) 1595 (1387) 44 (−182, 270) 337 (12, 661)7
Nighttime HF, ms2 311.5 (545.3) 0.7 (−84.1, 85.6) 356 (331) − 0.2 (−83.3, 82.8) − 10.0 (−120.0, 118.1)
1Values of change and main comparisons of changes between groups are presented as mean (95% CI) generated from estimated marginal means from ANCOVA.
2Not all data were analyzed due to poor-quality read-outs. FMD and prehyperemia brachial artery diameter: n = 42 (control) and 47 (almond). GTN: n = 32 (control) and 41
(almond). 24-h SBP, 24-h DBP, 24-h pulse, daytime SBP, DBP, and pulse: n = 45 (control) and 49 (almond). Nighttime SBP, DBP, and pulse: n = 40 (control) and 46 (almond).
24-h SDNN and 24-h rMSSD: n = 33 (control) and 29 (almond). Nighttime SDANN: n = 45 (control) and 47 (almond). Nighttime rMSSD: n = 45 (control) and 50 (almond).
Nighttime VLF and sleep-time HF: n = 45 (control) and 47 (almond). Nighttime SDANN: n = 45 (control) and 47 (almond).
3Median (IQR) for nighttime rMSSD, VLF, and HF data because they are nonnormally distributed. Mean ± SD for other data that are normally distributed.
4ANCOVA, adjusted for baseline outcome value and baseline BMI (mean difference in the change from baseline, almonds minus control). ANCOVA assumptions were met.
5Baseline value was different between control and almond group; independent t test was used, P < 0.05 indicated a significant difference.
6P < 0.00005.
7P < 0.05. cDBP, clinic diastolic blood pressure; cSBP, clinic systolic blood pressure; DBP, diastolic blood pressure; FMD, flow-mediated dilation; GTN, glycerol trinitrate;
HF, absolute power of the high-frequency band (0.15–0.04 Hz); rMSSD, root mean square of successive R-R interval differences; SBP, systolic blood pressure; SDANN, standard
deviation of the average NN intervals for each 5-min segment of heart rate variability recording; SDNN, standard deviation of normal-to-normal (NN) intervals; VLF, absolute
power of the very-low-frequency band (0.0033–0.04 Hz).
HRV, was increased during sleep-time by 337 ms2 (95% CI:
12, 661 ms2; P < 0.05) following almond consumption. There
were no significant group differences observed in changes in
blood pressure or in 24-h HRV.
Other cardiometabolic outcomes
As shown in Table 4, there were no treatment effects of diet
on BMI, waist circumference, percentage body fat (measured
by bioelectrical impedance), or truncal VAT or SAT volumes
(measured byMRI). Liver fat was unaffected by treatment, as was
pancreatic and skeletal muscle fat (measured by MRI and MRS).
Fasting plasma non-HDL and LDL cholesterol concentrations
were significantly reduced by almond snacks relative to control
by −0.22 mmol/L (95% CI: −0.42, −0.01 mmol/L; P = 0.037)
and−0.25 mmol/L (95% CI:−0.45,−0.04 mmol/L; P= 0.017),
respectively (Table 5), but there were no significant treatment
effects on HDL cholesterol, triacylglycerol, glucose, insulin,
HOMA-IR, adipokines, and markers of fatty liver (adiponectin,
leptin, resistin, fetuin-A, ALT, and GGT). Table 6 presents
fasting plasma fatty acid profiles in both groups. Plasma
concentrations of oleic acid, which made up 66% of total fatty
acid content of the almonds used in the study, were increased after
almond consumption relative to control by 228 μmol/L (95%
CI: 7, 449 μmol/L; P = 0.043), but no significant differences
in plasma concentrations of the other main fatty acid, linoleic
acid (22% of total fatty acid content of these almonds), nor any
other plasma fatty acids were observed. Furthermore, there were
no effects of treatment on fecal SCFA composition or total SCFA
concentrations (Table 7). Therewere no clear treatment effects on
metabolomic profiles (measured by NMR), although serum total
ω-3 concentrations decreased by −0.04 mmol/L (P= 0.031) and
citrate concentrations increased by 0.01 mmol/L (P = 0.018) in
the almond group relative to the control group (see Supplemental
Table 5).
Discussion
This study set out to test the hypothesis that substituting whole
almonds for typically consumed snacks would increase EDV,
decrease liver fat, and improve other markers of cardiometabolic
health. Replacing usual snacks with whole almonds, relative to a
neutral control snack, caused a 4% unit increase in EDV (FMD)
in healthy adults at above-average risk of CVD. According to
meta-analyses of clinical studies reporting the predictive value
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TABLE 4 Body composition and measures of ectopic fat, following randomization to almond and control snacks1
Control,2 nmax = 51 Almonds,2 nmax = 54
Main comparison
between groups4Baseline3 Change Baseline3 Change
Physical activity by
accelerometry,5 cpm
74.2 ± 17.1 1.5 (−4.0, 7.1) 74.6 ± 21.8 − 2.4 (−7.7, 2.8) − 4.0 (−11.6, 3.6)
BMI, kg/m2 27.1 ± 4.4 − 0.2 (−0.4, 0.0) 27.2 ± 4.5 0.1 (−0.1, 0.3) 0.2 (−0.1, 0.5)
WC, cm 93.3 ± 11.7 0.1 (−0.9, 1.2) 94.1 ± 12.2 − 0.6 (−1.6, 0.5) − 0.7 (−2.2, 0.8)
Body fat, % 31.1 ± 7.7 − 0.5 (−1.1, 0.0) 32.2 ± 7.7 0.3 (−0.3, 0.8) 0.8 (−0.0, 1.6)
MRI and 1H-MRS
Liver fat % 2.7 (2.5) 0.4 (−0.5, 1.3) 1.7 (1.7) 1.1 (0.1, 2.0) 0.7 (−0.6, 2.0)
IHL % 2.9 (4.0) 0.1 (−1.3, 1.6) 1.7 (2.3) − 0.6 (−2.1, 0.8) − 0.8 (−2.8, 1.3)
UI 0.21 ± 0.12 0.03 (−0.06, 0.12) 0.32 ± 0.20 0.01 (−0.08, 0.10) − 0.02 (−0.15, 0.10)
PUI 0.03 (0.11) 0.02 (−0.05, 0.10) 0.04 (0.21) 0.03 (−0.04, 0.10) 0.01 (−0.09, 0.11)
SI 0.77 (0.13) − 0.03 (−0.12, 0.05) 0.70 (0.35) − 0.01 (−0.10, 0.08) 0.02 (−0.10, 0.15)
Pancreatic fat, % 10.7 (3.8) 0.1 (−1.1, 1.3) 10.7 (3.2) 0.1 (−1.1, 1.4) 0.0 (−1.7, 1.8)
SAT, mL 13,703 ± 5290 678 (−41, 1397) 12,981 ± 5264 − 20 (−771, 732) − 697 (−1741, 347)
VAT, mL 3492 ± 1930 − 13 (−95, 69) 3009 ± 1889 34 (−50, 118) 47 (−71, 165)
IMCL 0.037 ± 0.027 0.002 (−0.005, 0.010) 0.030 ± 0.014 − 0.005 (−0.012, 0.003) − 0.007 (−0.018, 0.003)
EMCL 0.035 (0.027) 0.001 (−0.009, 0.010) 0.020 (0.015) − 0.001 (−0.011, 0.009) − 0.001 (−0.015, 0.013)
1Values of change and main comparison of the changes between groups are presented as mean (95% CI) generated from estimated marginal means from ANCOVA.
2MRI/MRS scanning was planned on a subset of study participants: n = 50 (25 per group). Not all data were analyzed due to technical problems. Physical activity
by accelerometery: n = 45 (control) and 50 (almond). BMI: n = 45 (control) and 50 (almond). WC: n = 49 (control) and 51 (almond). Body fat: n = 49 (control) and 52
(almond). Liver fat and pancreatic fat: n = 26 (control) and 24 (almond). IHL, UI, PUI, and SI: n = 22 (control) and 23 (almond). SAT: n = 24 (control) and 22
(almond). VAT: n = 23 (control) and 22 (almond). IMCL and EMCL: n = 23 (control) and 22 (almond).
3Median (IQR) for liver fat, IHL, PUI, SI, pancreatic fat, and EMCL data because they are nonnormally distributed. Mean ± SD for other data that are normally
distributed. Baseline biomarker values were not different between the 2 groups.
4ANCOVA, adjusted for baseline outcome value and baseline BMI (mean difference in change from baseline, almonds minus control); there were no significant
differences between groups. ANCOVA assumptions were met.
5Physical activity by accelerometery data were generated from heart rate variability monitoring. Cpm, counts per minute; EMCL, extramyocellular lipid; IHL,
intrahepatic lipid; IMCL, intramyocellular lipid; PUI, polyunsaturation index; SAT, subcutaneous fat; SI, saturation index; UI, unsaturation index; VAT, visceral fat;
WC, waist circumference; 1H-MRS, proton magnetic resonance spectroscopy.
would be equivalent to an adjusted RR reduction of 32% (pooled
RR: 0.92; 95% CI: 0.89, 0.96) per 1% increase in FMD) (27).
Thus, simply targeting the quality of snacks eaten between meals
can have a measurable beneficial impact on vascular health
and would be predicted to significantly reduce risk of CVD.
Studies are lacking on the effect of almonds on FMD in healthy
individuals (28), although previous meta-analyses of randomized
controlled trials of nut consumption (mainly walnuts, but also
2 studies on pistachios, 1 on almonds, and 1 on hazelnuts) in
participants with T2D or other health issues have reported smaller
effect sizes (0.4–0.8% unit differences) compared with the large
difference in the current study (29, 30). The improvement in
FMD observed in our current study was not accompanied by an
increase in prehyperemia diameter nor endothelium-independent
dilation (post-GTN administration), demonstrating that almond
consumption had a specific impact on nitric oxide–mediated
EDV.
Whole almonds have been shown to reduce postprandial
glycemia (31) and lipemia (32) compared with almond products
with a high lipid bioaccessibility where lipid has been mechani-
cally released from the plant cell walls. This can attenuate acute
increases in oxidative stress and inflammation postprandially (33,
34). Almonds also contain cardioprotective chemicals, including
l-arginine [essential in the process of nitric oxide synthesis
(33)], phenolic compounds, vitamin E, and folate. Whereas
concentrations of intracellular l-arginine already exceed that
required for nitric oxide synthesis (33), the increased intake of
(poly)phenolics, vitamin E, and folate could reduce oxidative
stress and inflammation, thus potentially improving nitric oxide
bioavailability (35–39).
Liver fat was a main outcome due to its central role in
metabolic regulation and as a predictive factor of CVD and T2D
risk (40). No effect of almond consumption was observed on
liver fat measured with MRI or 1H-MRS (both total percentage
and degree of saturation), nor inferred from biochemical markers
of liver health (fetuin-A or ALT/GGT). There were relatively
low amounts of liver fat in our study population at baseline,
with only 10% classified as having fatty liver (liver fat ≥5.5%).
Despite participants having higher concentrations of liver fat at
baseline (8–10%) in another recent trial, no impact of almond
consumption on liver fat was observed (56 g/d almonds compared
with isocaloric biscuits over 8 wk; n = 36) in participants
who were overweight/obese (41). These results demonstrate that
almond consumption does not modify liver fat in either direction
in a healthy population, despite almonds being a high-fat food.
The fact that liver fat did not increase could be due to the fact that
on average there was no shift to a positive energy balance and
also the low lipid bioaccessibility of almonds (42, 43).
Indicators of insulin sensitivity remained unaffected by the
almond intervention. These findings are consistent with previous
reports of almonds intakes of 15% of energy or 42–56 g/d in study
populations of individuals who were overweight/obese and/or at
increased risk of T2D (41, 44–46). The fact that insulin sensitivity
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TABLE 5 Circulating biomarkers of cardiometabolic risk following randomization to almond and control snacks1
Control,2 nmax = 51 Almonds,2 nmax = 54
Main comparison
between groups4Baseline3 Change Baseline3 Change
HOMA-IR 1.78 ± 1.38 0.21 (−0.17, 0.60) 1.64 ± 0.96 0.05 (−0.32, 0.41) − 0.16 (−0.70, 0.37)
Glucose, mmol/L 5.3 ± 0.6 0.02 (−0.14, 0.17) 5.3 ± 0.7 0.03 (−0.12, 0.18) 0.01 (−0.20, 0.23)
Insulin, mIU/L 7.1 ± 4.3 0.70 (−0.68, 2.07) 6.9 ± 3.5 0.08 (−1.24, 1.39) − 0.62 (−2.52, 1.28)
NEFA, mmol/L 0.66 ± 0.24 − 0.03 (−0.09, 0.04) 0.64 ± 0.24 − 0.00 (−0.06, 0.07) − 0.03 (−0.07, 0.12)
TC, mmol/L 5.26 ± 1.13 0.03 (−0.15, 0.20) 5.40 ± 0.93 − 0.18 (−0.35, −0.02) − 0.21 (−0.45, 0.03)
TAG, mmol/L 1.17 (0.69) − 0.11 (−0.20, 0.01) 1.07 (0.73) − 0.08 (−0.17, 0.02) 0.03 (−0.11, 0.16)
Non-HDL-C, mmol/L 3.92 ± 1.16 0.11 (−0.04, 0.26) 4.00 ± 0.98 − 0.11 (−0.25, 0.03 − 0.22 (−0.42, −0.01)5
LDL-C, mmol/L 3.63 ± 1.16 0.15 (0.01, 0.30) 3.74 ± 0.91 − 0.09 (−0.23, 0.05) − 0.25 (−0.45, −0.04)5
HDL-C, mmol/L 1.61 ± 0.45 0.04 (−0.04, 0.11) 1.66 ± 0.51 − 0.04 (−0.11, −0.03) − 0.08 (−0.18, 0.03)
TC:HDL-C 3.45 ± 0.91 − 0.04 (−0.15, 0.07) 3.47 ± 1.01 − 0.03 (−0.14, 0.07) 0.00 (−0.15, 0.16)
Leptin, μg/L 12.50 (13.41) − 0.34 (−2.08, 1.41) 17.49 (20.24) 0.25 (−1.44, 1.94) 0.59 (−1.86, 3.03)
Adiponectin, mg/L 7.64 (5.96) − 0.16 (−0.76, 0.44) 7.92 (5.86) − 0.14 (−0.72, 0.44) 0.02 (−0.82, 0.85)
ALT, IU/L 22.00 (9.8) − 0.46 (−3.52, 2.59) 22.10 (10.10) 1.31 (−1.63, 4.25) 1.77 (−2.47, 6.01)
GGT, IU/L 12.60 (11.80) − 0.77 (−3.58, 2.05) 15.20 (11.00) 0.92 (−1.79, 3.63) 1.69 (−2.22, 5.59)
Fetuin A, mg/L 698.60 ± 132.86 − 2.70 (−37.71, 32.32) 665.56 ± 136.83 15.91 (−18.08, 49.89) 18.60 (−30.33, 67.53)
Resistin, μg/L 5.25 ± 2.29 0.12 (−0.20, 0.44) 5.04 ± 1.79 − 0.01 (−0.32, 0.30) − 0.13 (−0.57, 0.31)
1Values of change and main comparisons of the changes between groups are presented as mean (95% CI) generated from estimated marginal means from
ANCOVA.
2Not all data were analyzed due to technical problems and sample loss. HOMA-IR and glucose: n = 48 (control) and 53 (almond). Insulin, NEFA, TC, TAG,
non-HDL-C, LDL-C, HDL-C, TC:HDL-C, ALT, GGT: n = 49 (control) and 53 (almond). Leptin, adiponectin, fetuin-A, and resistin: n = 49 (control) and 52 (almond).
3Median (IQR) for TAG, leptin, and GGT data because they are nonnormally distributed. Mean ± SD for other data that are normally distributed. Baseline
biomarker values were not different between the 2 groups.
4ANCOVA, adjusted for baseline outcome value and baseline BMI (mean difference in change from baseline, almonds minus control); P < 0.05 indicated a
significant difference. ANCOVA assumptions were met.
5P < 0.05 indicated a significant difference for values of mean difference between 2 groups. ALT, alanine aminotransferase; GGT, γ -glutamyltransferase; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NEFA, nonesterified fatty acid; TAG, triglyceride; TC, total cholesterol.
differences between groups in parameters of ectopic fat, assessed
byMRI imaging of visceral, pancreatic, and hepatic fat, andMRS
analysis of muscle lipids, nor in anthropometric assessments of
body fat. An important aim of the current study was to ensure
that both intervention armswere isoenergetic, and the consistency
in body weight over time and between treatments demonstrates
that this was achieved. Although observational studies report
inverse associations between tree nut and almond consumption
with BMI and WC (47, 48), average almond intakes are low and
therefore these associations are likely to indicate that almond
consumers have overall healthier diets leading to lower risk of
excess body fat (48). Bowen et al. (41) also reported no significant
differences in SAT and VATmeasured by MRI/MRS. In contrast,
displacement of snacks with 42 g/d almonds for 6 wk in human
TABLE 6 Plasma fatty acid profile following randomization to almond and control snacks1
Control, n = 48 Almonds, n = 53
Main comparison
between groups3FA, μmol/L Baseline2 Change Baseline2 Change
Palmitic (16:0) 2334.3 ± 992.4 − 105.6 (−322.3, 111.1) 2296.8 ± 933.1 53.6 (−152.6, 259.9) 159.2 (−140.1, 458.6)
Palmitoleic (16:1) 300.8 ± 175.8 − 18.2 (−42.1, 5.7) 282.9 ± 156.7 − 25.1 (−47.9, −2.4) − 7.0 (−40.0, 26.0)
Stearic (18:0) 690.4 ± 268.1 − 24.9 (−76.4, 26.6) 674.6 ± 241.2 5.2 (−43.8, 54.2) 30.1 (−41.0, 101.2)
Oleic (18:1n–9) 2300.4 ± 1032.1 − 111.3 (−271.1, 48.5) 2232.9 ± 915.3 116.6 (−35.5, 268.7) 227.9 (7.2, 448.7)4
Linoleic (18:2n–6) 2873.4 ± 1004.6 − 23.2 (−247.9, 201.6) 2853.6 ± 810.4 107.7 (−124.1, 303.6) 112.9 (−197.5, 423.3)
α-Linolenic (18:3n–3) 155.9 ± 81.6 4.3 (−16.5, 25.1) 134.6 ± 67.5 − 20.3 (−40.0, −0.6) − 24.6 (−53.4, 4.2)
γ -Linolenic (18:3n–6) 76.1 (76.5) − 9.5 (−21.2, 2.2) 70.8 (83.3) − 9.5 (−20.6, 1.7) 0.0 (−16.1, 16.2)
Homo-γ -linoleic (20:3n–6) 141.8 ± 65.3 − 2.8 (−17.1, 11.4) 136.5 ± 60.0 0.9 (−12.7, 14.4) 3.7 (−16.0, 23.4)
Arachidonic (20:4n–6) 601.5 ± 302.3 − 26.8 (−72.9, 19.4) 623.3 ± 243.4 15.0 (−28.9, 59.0) 41.8 (−22.0, 105.6)
Eicosapentaenoic (20:5n–3) 101.2 (77.3) 8.6 (−9.7, 26.9) 96.1 (81.1) − 11.6 (−29.0, 5.8) − 20.2 (−45.4, 5.1)
Docosatetraenoic (22:4n–6) 31.9 (25.3) − 1.1 (−3.5, 1.3) 29.0 (28.2) − 2.4 (−4.6, −0.1) − 1.3 (−4.6, 2.0)
Docosapentaenoic (22:5n–3) 47.9 ± 18.9 − 0.4 (−4.3, 3.6) 47.0 ± 19.9 − 3.6 (−7.4, 0.2) − 3.2 (−8.7, 2.2)
Docosapentaenoic (22:5n–6) 47.2 (59.8) − 0.2 (−4.9, 4.6) 49.0 (49.4) 1.3 (−3.3, 5.8) 1.5 (−5.1, 8.0)
Docosahexaenoic (22:6n–3) 184.9 ± 77.3 5.0 (−10.9, 20.9) 176.8 ± 81.0 − 5.9 (−21.0, 9.2) − 10.9 (−32.8, 11.1)
Total plasma FA 9913.6 ± 3685.5 − 303.4 (−1014.5, 407.7) 9741.3 ± 3275.5 201.4 (−475.2, 878.1) 504.8 (−477.4, 1487.0)
1Values of change and main comparisons of changes between groups are presented as mean (95% CI) generated from estimated marginal means from ANCOVA.
2Median (IQR) for γ -linolenic (18:3n–6), eicosapentaenoic (20:5n–3), docosatetraenoic (22:4n–6), and docosapentaenoic (22:5n–6) acids data because they are nonnormally
distributed. Mean ± SD for other data that are normally distributed. Baseline biomarker values were not different between the 2 groups.
3ANCOVA, adjusted for baseline outcome value and baseline BMI (mean difference in change from baseline, almonds minus control); P < 0.05 indicated a significant
difference. ANCOVA assumptions were met.
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TABLE 7 Fecal SCFAs from a subset of study population following random allocation to almond and control snacks1
Control, n = 17 Almonds, n = 18
Main comparison
between groups3SCFA, μmol/g Baseline2 Change Baseline2 Change
Acetic acid 50.1 (32.3) − 0.56 (−8.78, 9.90) 49.4 (31.8) 4.61 (−4.47, 13.68) 4.05 (−9.05, 17.15)
Propionic acid 12.8 (7.3) 2.26 (−2.14, 6.66) 13.8 (10.5) − 0.68 (−4.96, 3.59) − 2.94 (−9.13, 3.24)
Isobutyric acid 1.91(0.5) 0.04 (−0.41, 0.50) 1.6 (1.1) 0.27 (−0.18, 0.71) 0.22 (−0.42, 0.87)
Butyric acid 13.6 (8.7) 0.31 (−3.97, 4.59) 13.7 (12.9) 3.06 (−1.10, 7.21) 2.74 (−3.28, 8.77)
Isovaleric acid 2.2 (0.4) 0.10 (−0.43, 0.63) 1.9 (1.4) 0.30 (−0.22, 0.81) 0.20 (−0.55, 0.95)
Valeric acid 1.7 (1.2) 0.11 (−0.22, 0.45) 2.0 (0.8) 0.06 (−0.27, 0.38) − 0.06 (−0.52, 0.41)
Total SCFA 90.1 (52.0) 3.31 (−13.37, 20.0) 85.4 (68.0) 7.66 (−8.55, 23.87) 4.35 (−19.05, 27.75)
1Values of change and main comparisons of changes between groups are presented as mean (95% CI) generated from estimated marginal means from
ANCOVA.
2Median (IQR) because data are nonnormally distributed. Baseline biomarker values were not different between the 2 groups.
3ANCOVA, adjusted for baseline outcome value and baseline BMI (mean difference in change from baseline, almonds minus control). ANCOVA
assumptions were met. SCFA, short chain fatty acid.
adults with raised blood concentrations of LDL cholesterol, but
who were otherwise healthy (9), lowered abdominal and leg fat
measured by DXA despite no differences in body weight. One
factor that could influence regional fat distribution is the timing of
the snack intake. Evidence for this is provided by results of a 16-
wk trial in young Korean adults who consumed 56 g almonds/d
immediately before a meal, showing a reduction in visceral fat
without changes in body weight, but the same effect was not
demonstrated when almonds were consumed >2 h before or
after a meal (49). This could relate to a lowering of glycemic
and insulinemic responses induced by consumption of almonds
immediately before a meal.
Consistent with previous research, we observed a reduction
in LDL cholesterol, which is likely to be due to displacement
of snacks high in saturated fats with almonds that are rich in
unsaturated fats, phytosterols, and fiber. The average reduction
in the LDL fraction of 0.25 mmol/L reported here, relative to
control, is greater than that reported in a recent meta-analysis
of 15 previous almond intervention studies, that is, 0.14 mmol/L
(50).
In addition to endothelial function, other measures of cardio-
vascular function were measured, including BP and HRV. We
observed no difference in BP, in contrast to a recent meta-analysis
of 15 RCTs (50), which reported a significant reduction in DBP
in studies where >42 g almonds (for ≥3 wk) were consumed. A
unique finding of the study is the relative increase in the longer-
phase HRV parameter VLF during sleep, representing greater
parasympathetic regulation at night. Low VLF is predictive of
mortality (51) and associated with high biomarkers of systemic
inflammation (52). Over 24 h, however, there were no effects on
any parameter of HRV. During waking hours, parasympatheti-
cally driven longer-phase fluctuations in heart rate (e.g., VLF and
SD of the average NN intervals for each 5-min segment of a 24-
h HRV recording) in response to neurohormonal and circadian
physiological changes are likely to be largely overwhelmed by
larger sympathetically driven oscillations generated by physical
activities and emotional/psychological influences, unless mea-
sured under highly controlled conditions, for example, during
supine rest. It was previously reported that 4-wk consumption
of pistachios at 20% of EER increased HRV in the resting state
in adults with T2D compared with low-fat/high-carbohydrate
snacks (53).
A key strength of the current study was the considered design
of the control dietary intervention to ensure that treatment
effects on cardiometabolic risk factors were not the result of
a deterioration in diet quality in the control group. Although
the size of the decrease in potassium intake in the control
group was larger than the increase in potassium intake in
the almond group, all other differences in the changes from
baseline for macronutrients and micronutrients were attributable
to significant changes in dietary intake in the almond group.
Combining measures of liver fat ensured regional variability
in hepatic fat distribution was accounted for (by MRI of the
whole liver) but small changes could be detected using a more
sensitive method (MRS) (54). However, future studies could
also benefit from recruiting people with diagnosed fatty liver to
enable greater scope for diet-mediated change. Limitations of the
study were the fact that there were some differences between
groups in cardiometabolic disease risk factors at baseline,
despite the minimization of groups for age, sex, ethnicity, and
cardiometabolic risk score, and the similarity between groups at
baseline for screening variables. The difference in baseline FMD
values was unexpected, although the statistical analysis adjusted
for differences in baseline values. The imbalance in recruitment
by sex could mean that the results might not be as applicable
to men because they made up just 30% of the randomized
sample. Due to difficulties in obtaining fecal samples, it is likely
that SCFA analysis was statistically underpowered. The lack of
treatment effect contrasts with results from an in vitro digestion
model experiment, where butyrate significantly increased after
almond treatment (55). Lastly, there were 25 participants who
did not complete usable 4-d food diaries and therefore accurate
dietary intake data are missing for nearly one-quarter of the
sample population, although inspection of 24-h dietary recalls
indicated that compliance did not differ in these participants.
In conclusion, the results of this trial show that replacing
typical snacks with almonds can have a meaningful impact on
daily nutrient intakes and can improve endothelial function,
cardiac autonomic function, and lower LDL cholesterol. How-
ever, isoenergetic snack substitution in this trial did not modify
regional fat deposition and thereforemarkers of insulin sensitivity
were unaffected. The degree of improvement in endothelial
function and LDL cholesterol concentrations suggests that
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snacks has the potential to reduce CVD risk by ≤30% and
therefore could play a powerful role in enhancing cardiovascular
health.
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